JP2016522826A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016522826A5 JP2016522826A5 JP2016514042A JP2016514042A JP2016522826A5 JP 2016522826 A5 JP2016522826 A5 JP 2016522826A5 JP 2016514042 A JP2016514042 A JP 2016514042A JP 2016514042 A JP2016514042 A JP 2016514042A JP 2016522826 A5 JP2016522826 A5 JP 2016522826A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutically acceptable
- acceptable salt
- hydroxycyclopentyl
- ylamino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims description 33
- 238000000034 method Methods 0.000 claims description 30
- 206010028980 Neoplasm Diseases 0.000 claims description 26
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 18
- 201000005202 lung cancer Diseases 0.000 claims description 18
- 208000020816 lung neoplasm Diseases 0.000 claims description 18
- -1 4-((1S) -2,3-dihydro-1H-inden-1-ylamino) -7H-pyrrolo [2,3-d] pyrimidin-7-yl Chemical group 0.000 claims description 16
- 201000010536 head and neck cancer Diseases 0.000 claims description 16
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 16
- FIYXUOWXHWJDAM-UHFFFAOYSA-N methyl sulfamate Chemical compound COS(N)(=O)=O FIYXUOWXHWJDAM-UHFFFAOYSA-N 0.000 claims description 16
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 14
- 229940123237 Taxane Drugs 0.000 claims description 11
- MPUQHZXIXSTTDU-QXGSTGNESA-N sulfamic acid [(1S,2S,4R)-4-[4-[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]-7-pyrrolo[2,3-d]pyrimidinyl]-2-hydroxycyclopentyl]methyl ester Chemical compound C1[C@H](O)[C@H](COS(=O)(=O)N)C[C@H]1N1C2=NC=NC(N[C@@H]3C4=CC=CC=C4CC3)=C2C=C1 MPUQHZXIXSTTDU-QXGSTGNESA-N 0.000 claims description 10
- 206010005003 Bladder cancer Diseases 0.000 claims description 9
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 9
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 9
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 9
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 9
- 201000004101 esophageal cancer Diseases 0.000 claims description 9
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 9
- 201000002528 pancreatic cancer Diseases 0.000 claims description 9
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 9
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 9
- 206010006187 Breast cancer Diseases 0.000 claims description 8
- 208000026310 Breast neoplasm Diseases 0.000 claims description 8
- 206010009944 Colon cancer Diseases 0.000 claims description 8
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 8
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims description 8
- 229960004562 carboplatin Drugs 0.000 claims description 8
- 208000029742 colonic neoplasm Diseases 0.000 claims description 8
- 229960003668 docetaxel Drugs 0.000 claims description 8
- 229960001592 paclitaxel Drugs 0.000 claims description 8
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims description 7
- 229930012538 Paclitaxel Natural products 0.000 claims description 6
- 229960004316 cisplatin Drugs 0.000 claims description 4
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 4
- 108010058566 130-nm albumin-bound paclitaxel Proteins 0.000 claims description 2
- KLNFSAOEKUDMFA-UHFFFAOYSA-N azanide;2-hydroxyacetic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OCC(O)=O KLNFSAOEKUDMFA-UHFFFAOYSA-N 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 229950007221 nedaplatin Drugs 0.000 claims description 2
- 229960001756 oxaliplatin Drugs 0.000 claims description 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 2
- 229950005566 picoplatin Drugs 0.000 claims description 2
- IIMIOEBMYPRQGU-UHFFFAOYSA-L picoplatin Chemical compound N.[Cl-].[Cl-].[Pt+2].CC1=CC=CC=N1 IIMIOEBMYPRQGU-UHFFFAOYSA-L 0.000 claims description 2
- 229960005399 satraplatin Drugs 0.000 claims description 2
- 190014017285 satraplatin Chemical compound 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 3
- 210000000481 breast Anatomy 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 6
- 229960005277 gemcitabine Drugs 0.000 description 6
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361822994P | 2013-05-14 | 2013-05-14 | |
| US61/822,994 | 2013-05-14 | ||
| US201361874393P | 2013-09-06 | 2013-09-06 | |
| US61/874,393 | 2013-09-06 | ||
| US201361891943P | 2013-10-17 | 2013-10-17 | |
| US61/891,943 | 2013-10-17 | ||
| PCT/US2014/037888 WO2014186388A2 (en) | 2013-05-14 | 2014-05-13 | Administration of nedd8-activating enzyme inhibitor and chemotherapeutic agents |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019058196A Division JP2019112461A (ja) | 2013-05-14 | 2019-03-26 | Ｎｅｄｄ８活性化酵素阻害剤及び化学療法剤の投与 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016522826A JP2016522826A (ja) | 2016-08-04 |
| JP2016522826A5 true JP2016522826A5 (https=) | 2017-06-22 |
| JP6556701B2 JP6556701B2 (ja) | 2019-08-07 |
Family
ID=51898991
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016514042A Expired - Fee Related JP6556701B2 (ja) | 2013-05-14 | 2014-05-13 | Ｎｅｄｄ８活性化酵素阻害剤及び化学療法剤の投与 |
| JP2019058196A Withdrawn JP2019112461A (ja) | 2013-05-14 | 2019-03-26 | Ｎｅｄｄ８活性化酵素阻害剤及び化学療法剤の投与 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019058196A Withdrawn JP2019112461A (ja) | 2013-05-14 | 2019-03-26 | Ｎｅｄｄ８活性化酵素阻害剤及び化学療法剤の投与 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20160074404A1 (https=) |
| EP (1) | EP2996773B1 (https=) |
| JP (2) | JP6556701B2 (https=) |
| CN (1) | CN105407973A (https=) |
| CA (1) | CA2923752A1 (https=) |
| WO (1) | WO2014186388A2 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG175929A1 (en) | 2009-05-14 | 2011-12-29 | Millennium Pharm Inc | Hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate |
| WO2017189856A2 (en) * | 2016-04-27 | 2017-11-02 | University Of Virginia Patent Foundation | Compositions and methods for treating cancer |
| WO2023242235A1 (en) * | 2022-06-14 | 2023-12-21 | Scandion Oncology A/S | Abcg2 inhibitor and nae inhibitor for the treatment of cancer |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1848718E (pt) | 2005-02-04 | 2012-10-11 | Millennium Pharm Inc | Inibidores de enzimas de activação e1 |
| KR101450535B1 (ko) | 2006-02-02 | 2014-10-14 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | Ｅ１ 활성화 효소의 억제제 |
| EA201501088A1 (ru) | 2006-08-08 | 2017-01-30 | Миллениум Фармасьютикалз, Инк. | Гетероарильные соединения, применяемые в качестве ингибиторов e1 активирующих ферментов |
| US8008307B2 (en) | 2006-08-08 | 2011-08-30 | Millennium Pharmaceuticals, Inc. | Heteroaryl compounds useful as inhibitors of E1 activating enzymes |
| WO2009042013A1 (en) | 2007-08-02 | 2009-04-02 | Millennium Pharmaceuticals, Inc. | Process for the synthesis of e1 activating enzyme inhibitors |
| SG175929A1 (en) | 2009-05-14 | 2011-12-29 | Millennium Pharm Inc | Hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate |
| JP2013541587A (ja) * | 2010-11-05 | 2013-11-14 | ミレニアム ファーマシューティカルズ， インコーポレイテッド | Ｎｅｄｄ８活性化酵素阻害剤の投与 |
| JP2014503597A (ja) | 2011-01-31 | 2014-02-13 | セルジーン コーポレイション | シチジンアナログの医薬組成物及びその使用方法 |
| JP2015502137A (ja) * | 2011-10-07 | 2015-01-22 | ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | Ｅ１酵素変異体およびその用途 |
| KR101987861B1 (ko) | 2011-11-03 | 2019-06-11 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | Nedd-8 활성화 효소 억제제 및 저메틸화제의 투여 |
-
2014
- 2014-05-13 CA CA2923752A patent/CA2923752A1/en not_active Abandoned
- 2014-05-13 EP EP14797156.8A patent/EP2996773B1/en active Active
- 2014-05-13 WO PCT/US2014/037888 patent/WO2014186388A2/en not_active Ceased
- 2014-05-13 US US14/889,571 patent/US20160074404A1/en not_active Abandoned
- 2014-05-13 CN CN201480033555.4A patent/CN105407973A/zh active Pending
- 2014-05-13 JP JP2016514042A patent/JP6556701B2/ja not_active Expired - Fee Related
-
2018
- 2018-05-15 US US15/980,165 patent/US10786505B2/en not_active Expired - Fee Related
-
2019
- 2019-03-26 JP JP2019058196A patent/JP2019112461A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Higuchi et al. | Definitive chemoradiation therapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) in advanced esophageal cancer: a phase 2 trial (KDOG 0501-P2) | |
| JP2017533223A5 (https=) | ||
| JP2014512356A5 (https=) | ||
| FI4403228T3 (fi) | Her2:n dimerisaation estäjä pertutsumabin käyttötapoja ja sitä sisältävä tuote | |
| JP2016528162A5 (https=) | ||
| JP2014528423A5 (https=) | ||
| JP2016520528A5 (https=) | ||
| JP2020523356A5 (https=) | ||
| JP2019521180A5 (https=) | ||
| JP2016515628A5 (https=) | ||
| TWI544920B (zh) | Ｎ－羥基－４－｛２－［３－（ｎ，ｎ－二甲基胺基甲基）苯並呋喃－２－基羰基胺基］乙氧基｝苯甲醯胺之新穎投藥法 | |
| JP2022527334A5 (https=) | ||
| JP2019506392A5 (https=) | ||
| Sun et al. | A retrospective comparison of taxane and fluorouracil-based chemoradiotherapy in patients with inoperable esophageal squamous cell carcinoma | |
| JP2017516827A5 (https=) | ||
| JP2014530181A5 (https=) | ||
| JP2016522826A5 (https=) | ||
| JP2015510945A5 (https=) | ||
| Feng et al. | Prolonged adjuvant capecitabine chemotherapy improved survival of stage IIIA gastric cancer after D2 gastrectomy | |
| Seo et al. | Treatment outcomes of oxaliplatin, 5-FU, and leucovorin as salvage therapy for patients with advanced or metastatic gastric cancer: a retrospective analysis | |
| JP6458007B2 (ja) | 抗腫瘍性白金錯体を含有する抗腫瘍剤及び抗腫瘍効果増強剤 | |
| RU2014141615A (ru) | Новое противоопухолевое средство, включающее комбинацию трех агентов | |
| Seo et al. | Synthesis of flavokawain B and its anti-proliferative activity against gefitinib-resistant non-small cell lung cancer (NSCLC) | |
| CN103442708A (zh) | 治疗性处理 | |
| JP2023534300A5 (https=) |